Trial Watch—Oncolytic viruses and cancer therapy

Jonathan PolINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France;Gustave Roussy Cancer Campus, Villejuif, France

Aitziber BuquéINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France;Gustave Roussy Cancer Campus, Villejuif, France

Fernando ArandaGroup of Immune receptors of the Innate and Adaptive System, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Norma BloyINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France;Gustave Roussy Cancer Campus, Villejuif, France

Isabelle CremerINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 13, Center de Recherche des Cordeliers, Paris, France

Alexander EggermontGustave Roussy Cancer Campus, Villejuif, France

Philippe ErbsTransgene S.A., Illkirch-Graffenstaden, France

Jitka FucikovaSotio, Prague, Czech Republic;Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic

Jérôme GalonINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France

Jean-Marc LimacherTransgene S.A., Illkirch-Graffenstaden, France

Xavier PrevilleTransgene S.A., Illkirch-Graffenstaden, France

Catherine Sautès-FridmanINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 13, Center de Recherche des Cordeliers, Paris, France

Radek SpisekSotio, Prague, Czech Republic;Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic

Laurence ZitvogelGustave Roussy Cancer Campus, Villejuif, France;INSERM, U1015, CICBT507, Villejuif, France

Guido KroemerINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France;Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France;Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected] [email protected]

Lorenzo GalluzziINSERM, U1138, Paris, France;Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France;Université Pierre et Marie Curie/Paris VI, Paris, France;Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France;Gustave Roussy Cancer Campus, Villejuif, FranceCorrespondence[email protected] [email protected]

show all

Trial Watch—Oncolytic viruses and cancer therapy

Table 1. Clinical trials recently started to investigate the safety and efficacy of oncolytic viruses in cancer patients*Footnote

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trial Watch—Oncolytic viruses and cancer therapy

Figures & data

Table 1. Clinical trials recently started to investigate the safety and efficacy of oncolytic viruses in cancer patients*Footnote

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date